Lay Title: 68Ga-PSMA-11 PET/CT for the Diagnosis of Bone Metastases in Patients with Prostate Cancer and Biochemical Progression During Androgen Deprivation Therapy
Technical Title: Head-to-Head Comparison of 68Ga-PSMA-11 PET/CT with 99mTc-MDP Bone Scan and CT for Detection of M1b disease in Prostate Cancer Patients with Biochemical Progression During ADT
Disease Type: Prostate Cancer (PCa)
Basic information: This phase II trial studies how well 68Ga-PSMA-11 positron emission tomography (PET)/computed tomography (CT) works in detecting the spread of cancer to the bones (bone metastasis) in patients with prostate cancer and increased PSA after treatment (biochemical recurrence) during androgen deprivation therapy. Diagnostic procedures, such as 68Ga-PSMA-11 PET/CT, may help find and diagnose prostate cancer and find out how far the disease has spread.
Research Procedures: This trial will enroll an estimated 102 patients with prostate cancer whose disease has progressed during androgen deprivation therapy. Patients are eligible for enrollment irrespective of whether the patient has preexisting non-metastatic or metastatic, castration sensitive or castration resistant disease.
All patients will undergo a PSMA imaging with 68Ga-PSMA-11 PET/CT. Patients must have a bone scan scheduled or performed within 30 days of PSMA PET. Participation duration can be up to 1 month.
For More Detailed Information, Contact: